高危型HPV检测在宫颈癌监测中的作用
该回顾性研究纳入单一机构2012年5月至2019年12月诊治的262例宫颈癌患者,其中169例在监测期接受hrHPV检测。24例复发患者中5例(21%)监测期hrHPV阳性,无复发患者中36例(24%)阳性(p=0.67);hrHPV检测未发现任何复发。作者认为阳性hrHPV检测与复发无关,不支持常规用于评估复发。
要点
- 在169例监测期接受hrHPV检测的患者中,41例(24%)至少一次hrHPV阳性。
- 复发患者hrHPV阳性率21%(5/24) vs 无复发患者24%(36/145),p=0.67。
- hrHPV检测未发现任何复发,作者认为不支持常规用hrHPV评估宫颈癌复发。
核心结论
- 监测期hrHPV阳性与宫颈癌复发无关,但会导致额外的检查和操作。
- 作者认为研究结果不支持常规使用hrHPV检测评估宫颈癌复发。
研究设计与样本
- 回顾性识别单一机构2012年5月至2019年12月诊治的宫颈癌患者,纳入鳞癌、腺癌、腺鳞癌和神经内分泌组织学类型。
- 排除治疗后3个月内进展或监测记录不足1年的患者,最终262例符合纳入标准,其中169例监测期接受hrHPV检测并纳入主要结局分析。
主要发现
- 262例患者中诊断复发58例(22%),复发最常通过监测影像学检查发现(71%)。
- 169例接受hrHPV检测的患者中,41例(24%)至少一次hrHPV阳性,24例(14%)诊断复发。
- 24例复发患者中5例(21%)监测期至少一次hrHPV阳性,145例无复发患者中36例(24%)至少一次hrHPV阳性(p=0.67)。
- hrHPV检测未发现任何复发。
临床怎么用
- 原文未据此给出推荐,作者认为研究结果不支持常规使用hrHPV检测评估宫颈癌复发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: While high-risk HPV (hrHPV) testing is not formally recommended as a surveillance modality in patients with a history of cervical cancer, it is often performed in routine practice. It is unclear whether the presence of hrHPV infection after cervical cancer treatment is associated with recurrent disease. METHODS: Patients with a cervical cancer diagnosis who were seen in a single institution between May 2012 and December 2019 were retrospectively identified. Squamous cell, adenocarcinoma, adenosquamous, and neuroendocrine histologies were included. Those with cancer progression within 3 months of treatment or < 1 year of documented surveillance were excluded. Patients who had hrHPV testing performed were included in the primary outcome analysis. RESULTS: Of the 262 patients meeting inclusion criteria, 58 (22%) recurrences were diagnosed, and recurrence was most commonly detected by a surveillance imaging study (71%). Among the 169 patients that were tested for hrHPV during the surveillance period, 41 (24%) had at least one positive hrHPV test. Recurrent disease was diagnosed in 24 (14%). Of the 24 patients with recurrent disease, 5 (21%) had at least one positive hrHPV test during surveillance, versus 36 (24%) of 145 patients without recurrent disease (p = 0.67). No recurrences were detected by hrHPV testing. CONCLUSIONS: Positive hrHPV testing in the surveillance setting was not associated with cervical cancer recurrence but did lead to additional studies and procedures. Our findings do not support the routine use of hrHPV testing for the evaluation of cervical cancer recurrence.
引用
- Aryasomayajula C, Chanana A, Tandel M, et al. The role of high-risk HPV testing in cervical cancer surveillance. Gynecol Oncol. 2021. PMID: 34836678. doi:10.1016/j.ygyno.2021.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。